Douglas Loesch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Douglas Loesch has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Andrea R. V. R. Horimoto
Department of Genetics, School of Medicine (A.R.V.R.H., N.F.), University of North Carolina, Chapel Hill
1 shared publication Andrea Rivera-Valdivia
Neurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, Peru
1 shared publicationAndres Lescano
Department of Genetics, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay
1 shared publicationArtur Schumacher-Schuh
Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
1 shared publicationBruno L. Santos-Lobato
Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Brazil
1 shared publication- Carlos Cosentino
Movement Disorders Unit Instituto Nacional de Ciencias Neurologicas Lima Peru
1 shared publication
Latest Publications
- Open Access
Genome-wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients
Background: Parkinson's disease is the second most common neurodegenerative disorder and affects people from all ethnic backgrounds, yet little is known about the genetics of Parkinson's disease in non-European populations. In addition, the overall identification of copy number variants at a genome-wide level has been understudied in Parkinson's disease patients. Objectives: To understand the genome-wide burden of copy number variants in Latinos and its association with Parkinson's disease. Methods: We used genome-wide genotyping data from 747 Parkinson's disease patients and 632 ancestry matched controls from the Latin American Research Consortium on the Genetics of Parkinson's disease. Results: Genome-wide copy number burden analysis showed no difference between patients vs. controls, whereas patients were significantly enriched for copy number variants overlapping known Parkinson's disease genes compared to controls (Odds Ratio: 3.97 [1.69 - 10.5], P = 0.018). PARK2 showed the strongest copy number burden, with 20 copy number variant carriers. These patients presented an earlier age of disease onset compared to patients with other copy number variants (median age at onset: 31 years vs. 57 years, P = 7.46 x 10-7). Conclusions: We found that Parkinson's disease patients are significantly enriched with copy number variants affecting known Parkinson's disease genes. We also identified that out of 250 patients with early-onset disease, 5.6% carried a copy number variant on PARK2 in our cohort. Our study is the first to analyze genome-wide copy number variants association in Latino Parkinson's disease patients and provides insights about this complex disease in this understudied population.
Open AccessGenome-wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients
Background: Parkinson's disease is the second most common neurodegenerative disorder and affects people from all ethnic backgrounds, yet little is known about the genetics of Parkinson's disease in non-European populations. In addition, the overall identification of copy number variants at a genome-wide level has been understudied in Parkinson's disease patients. Objectives: To understand the genome-wide burden of copy number variants in Latinos and its association with Parkinson's disease. Methods: We used genome-wide genotyping data from 747 Parkinson's disease patients and 632 ancestry matched controls from the Latin American Research Consortium on the Genetics of Parkinson's disease. Results: Genome-wide copy number burden analysis showed no difference between patients vs. controls, whereas patients were significantly enriched for copy number variants overlapping known Parkinson's disease genes compared to controls (Odds Ratio: 3.97 [1.69 - 10.5], P = 0.018). PARK2 showed the strongest copy number burden, with 20 copy number variant carriers. These patients presented an earlier age of disease onset compared to patients with other copy number variants (median age at onset: 31 years vs. 57 years, P = 7.46 x 10-7). Conclusions: We found that Parkinson's disease patients are significantly enriched with copy number variants affecting known Parkinson's disease genes. We also identified that out of 250 patients with early-onset disease, 5.6% carried a copy number variant on PARK2 in our cohort. Our study is the first to analyze genome-wide copy number variants association in Latino Parkinson's disease patients and provides insights about this complex disease in this understudied population.